TargetMol

Ulodesine

Product Code:
 
TAR-T67822L
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20°C
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T67822L-1mg1mg£182.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T67822L-1mL1 mL * 10 mM (in DMSO)£325.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T67822L-5mg5mg£349.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T67822L-10mg10mg£523.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T67822L-25mg25mg£785.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T67822L-50mg50mg£1,058.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T67822L-100mg100mg£1,412.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T67822L-500mg500mg£2,761.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Ulodesine is a purine nucleoside phosphorylase (PNP) inhibitor that inhibits PNP with an IC50 value of 2.293 nM/L. Ulodesine may be used to study hyperuricaemia.
CAS:
548486-59-5
Molecular Weight:
264.28
Pathway:
Metabolism
Purity:
1
SMILES:
C(C=1C2=C(NC1)C(=O)N=CN2)N3C[C@H](CO)[C@@H](O)C3
Target:
Endogenous Metabolite

References

Diaz-Torn? C, et al. New medications in development for the treatment of hyperuricemia of gout. Curr Opin Rheumatol. 2015;27(2):164-169. Shahid H, et al. Investigational drugs for hyperuricemia. Expert Opin Investig Drugs. 2015;24(8):1013-1030. Yang X, et al. Establishment of a novel hyperuricemiaanimal model using mice and assessment ofhyporuricemia action of PNP inhibitor Ulodesine. Chinese Pharmacological Bulletin, 2017: 883-886.